We isolated a 204-base pair carcinoembryonic antigen (CEA) promoter core region from a CEA-producing human colorectal carcinoma (CRC) and constructed retrovirus vectors carrying the expression cassette consisting of the CEA promoter core region and the cytosine deaminase (CD) gene. pCD2 retrovirus carrying the CD gene directed by the retrovirus long terminal repeat promoter served as a control vector. An in vitro study showed that the CEA promoter conferred CEA-producing cell-selective CD expression, specifically when the CD expression cassette was inserted into the 3Ј long terminal repeat of the retrovirus vector. CD-modified CRC xenografts in nude mice were sensitive to 5-fluorocytosine and caused a profound bystander effect on the unmodified CRC. When nude mice harboring intraperitoneally disseminated CRCs were injected intraperitoneally with the CD expression cassette-carrying retrovirus-producing cells, CD transduction into the disseminated CRCs and bone marrow (BM) was observed. CD expression was, however, restricted to CRCs, and it was observed in both CRCs and BM of mice injected with pCD2 retrovirus-producing cells, resulting in better therapeutic outcomes without BM suppression. These results indicate that effective and safe in vivo gene therapy for CRC may be feasible by transferring the CD gene controlled by the CEA promoter core region.
G ene therapy may be a promising therapeutic approach for the treatment of colorectal carcinoma (CRC). Among the various strategies of gene therapy for CRC, the delivery of a suicide gene into CRC followed by the corresponding prodrug treatment, such as a combination of Escherichia coli cytosine deaminase (CD) gene transduction and 5-fluorocytosine (5-FC), is one of the most promising approaches. CD is an enzyme that is found in many bacteria and fungi and deaminates cytosine to uracil, whereas normal mammalian cells do not possess CD. CD also deaminates the relatively nontoxic 5-FC to the highly toxic 5-fluorouracil (5-FU), which has been used most commonly for the treatment of CRC. 5-FU causes cell death by inhibiting both DNA and RNA synthesis; 1 however, its effectiveness is limited because of its systemic toxicity, specifically bone marrow (BM) suppression. In contrast, 5-FC is not toxic to humans at therapeutic doses. 2 Mullen et al 3 and Huber et al 4 genetically modified tumor cells to express CD.
They implanted the modified cells into mice, administered 5-FC intraperitoneally (i.p.), and demonstrated local 5-FU generation and antitumor effects. Compared with ex vivo gene therapy, in vivo gene therapy is definitely applicable for the treatment of CRC, because ex vivo gene therapy requires invasive surgical procedures to collect target cells for genetic modification. To employ in vivo gene therapy protocols in clinical trials, it is essential to achieve CRC-selective transduction or expression of the CD gene; otherwise, systemic toxicity will result from 5-FC administration. Carcinoembryonic antigen (CEA) is a tumor-associated marker that is overexpressed in tumors of epithelial cell origin, such as colon, stomach, pancreas, lung, ovary, and breast cancers. 5 Markedly increased transcriptional activity of the CEA gene in CRC compared with the normal colon has been demonstrated. 6 An ϳ400-base pair (bp) CEA promoter region was isolated from the human genomic library by Schrewe et al 7 and was employed to a direct cancer cell-selective expression of exogenous genes in human CRC, 8 lung cancer, 9 gastric cancer, 10 and pancreatic cancer, 11 in which CEA was highly produced. Richards et al 12 have identified a promising CEA promoter region (located between Ϫ90 and ϩ69 bp upstream from the transcriptional start site) and have demonstrated that the CEA promoter can induce CEA-producing CRC cell-selective expression of the CD gene. We have also isolated putative CEA promoter core regions consisting of 419 and 204 bp from a high CEA-producing human CRC and have demonstrated that these CEA promoter regions possess similar promoter activity, resulting in a similar CEA-producing CRC cell-selective expression of a luciferase reporter gene 13 and the CD gene. 14 In the present study, replication-deficient retroviruses carrying the CD gene under the transcriptional control of the 204-bp CEA promoter core region were constructed, and the ability of the retrovirus vectors to selectively confer CEA-producing CRC cells sensitive to 5-FC was assessed. We also examined whether in vivo gene therapy against CRC with retroviruses carrying the CD gene under the control of the 204-bp CEA promoter core region results in CRC-selective CD expression without systemic toxicity.
MATERIALS AND METHODS

Cell lines and cell culture
The human CRC cell lines WiDr, LoVo, and SW1463, the human gastric carcinoma cell line MKN1, the human hepatocellular carcinoma cell line Hep3B, the amphotropic retrovirus packaging cell line PA317, the ecotropic retrovirus packaging cell line Psi2, and the murine embryo fibroblast cell line NIH3T3 were purchased from the American Type Culture Collection (Manassas, Va). The human renal cell carcinoma cell line RC9406 was established by the Department of Microbiology of the Second Military Medical University (Shanghai, China). The cells were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf sera, 100 U/mL ampicillin, and 100 mg/mL streptomycin at 37°C in a humidified 5% CO 2 atmosphere. CEA secretion of cells was measured following a 7-day accumulation using the CEA enzyme immunoassay monoclonal one-step kit (Abbott Laboratories, Abbott, Ill). CEA expression was standardized based on the protein content of cell pellets using a protein assay kit (BioRad, Hercules, Calif).
Construction of retrovirus vectors
Construction of the CEA204/CD retrovirus vector that carries the bacterial CD gene under the transcriptional control of the CEA promoter core region has been described elsewhere, 14 and a diagram is shown in Figure 1 . The 1.5-kilobase (kb) CD gene fragment, excised from the pCD2 retrovirus vector, 15 contains a unique ATG eukaryotic start codon, a 1283-bp CD coding region, a TGA termination codon, and a 239-bp uncoding region at the 3Ј terminal. The CEA promoter core region, located between Ϫ135 and ϩ69 bp upstream from the transcriptional start site of the CEA gene, was isolated from a high CEA-producing human CRC as described previously. 13 The expression cassette consisting of the CEA promoter core region and the CD gene was inserted into the retrovirus construct in a reverse orientation. LNCX, 16 pCD2, and blunted with the Klenow fragment, ligated with XbaI adapters, and subsequently inserted into the XbaI site in the U3 region of the 3Ј long terminal repeat (LTR) of the G1Na retrovirus vector in a sense orientation to create the G1NaCEA204/CD retrovirus vector (Fig 1) .
Recombinant retrovirus production
LNCX, pCD2, CEA204/CD, and G1NaCEA204/CD retrovirus vector constructs were converted to the corresponding retroviruses by the transinfection protocol. 18, 19 The retrovirus vector constructs were transfected into the ecotropic retroviruspackaging cell line Psi2 using Lipofectamine reagent (Life Technologies, Grand Island, NY) according to the protocol provided by the manufacturer. Filtered supernatants from ecotropic retrovirus-producing cells were then added to the amphotropic retrovirus-packaging cell line PA317 in the presence of 8 g/mL polybrene (Sigma, St. Louis, Mo). After selection with 400 g/mL active G418 (Life Technologies), individual G418-resistant clones were isolated and tested for the ability to produce recombinant retroviruses. The titers of recombinant particles were determined by infecting NIH3T3 cells with serial dilutions of the culture medium from each clone as described previously. 20 The high-titer LNCX, pCD2, CEA204/CD, and G1NaCEA204/CD retrovirus-producing clones selected for subsequent experiments had titers of ϳ2.5 ϫ 10 7 , 2.3 ϫ 10 7 , 2.3 ϫ 10 7 , and 0.8 ϫ 10 7 colony-forming units (CFU)/mL, respectively. Culture supernatants of hightiter retrovirus-producing clones were collected, passed through a 0.45-m pore filter (Millipore, Bedford, Mass), and stored at Ϫ70°C. They were confirmed to be free of replica- tion-competent retroviruses by reverse transcription-polymerase chain reaction (RT-PCR) as described previously 21 and served as sources for infectious recombinant retroviruses.
In vitro gene transfer and evaluation of sensitivity to 5-FC
The cells were infected with retroviruses in the presence of 8 g/mL polybrene as described previously. 22 After selection with G418, the bulk of G418-resistant cells were expanded and used as retrovirus-infected cells for the subsequent experiments. The cells were plated at a density of 1 ϫ 10 3 cells/well in 96-well, flat-bottom tissue culture plates in the media containing various concentrations (100 M-50,000 M) of 5-FC (Sigma) for 4 days, and the number of viable cells was determined using the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide conversion assay as described previously. 23 The 50% inhibiting concentration (IC 50 ), defined as the dose required for achieving 50% cytotoxicity, for each cell line was calculated using a curve-fitting parameter based on the Marquardt method. 24 The sensitivity of the cells to 5-FU was estimated in a similar manner.
In vivo bystander effect of CD gene-modified CRC xenografts
To examine the in vivo bystander effect of CD gene-modified CRC on unmodified CRC, xenograft experiments were performed. Parental and CEA204/CD retrovirus-infected LoVo cells were suspended in serum-free medium at a concentration of 2 ϫ 10 7 cells/mL. Eight-week-old female BALB/c-nu/nu mice were purchased from the Experimental Animal Center (Shanghai, China) and were inoculated subcutaneously (s.c.) in the flank regions with 100 L of parental or CEA204/CD retrovirus-infected LoVo cells. The animals in group 3 were inoculated s.c. with 200 L of a mixture of the parental and CEA204/CD retrovirus-infected LoVo cells. Each group consisted of five animals. At 25 days postinoculation, 5-FC (700 mg/kg body weight/day) was administered i.p. into the animals for 7 consecutive days. Tumor development was observed until the first animal died. The tumor volume was calculated as described previously. 25 All animal experiments were performed with approved protocols and in accordance with the recommendations for the proper care and use of laboratory animals.
In vivo gene transfer into mice with i.p. disseminated CRCs
Athymic BALB/c-nu/nu mice were injected i.p. with 2 ϫ 10 6 parental LoVo cells suspended in 100 L of serum-free medium and divided randomly into the following five groups according to treatment schedules: group 1, injection of LNCX retrovirus-producing cells followed by 5-FC treatment; group 2, injection of pCD2 retrovirus-producing cells followed by 5-FC treatment; group 3, injection of CEA204/CD retrovirusproducing cells followed by 5-FC treatment; group 4, injection of CEA204/CD retrovirus-producing cells followed by phosphate-buffered saline (PBS) treatment; group 5, injection of serum-free medium followed by 5-FU treatment. Each group consisted of seven animals. In groups 1-4, the mice were injected i.p. with 2 ϫ 10 6 retrovirus-producing cells suspended in 200 L of serum-free medium containing 16 g/mL polybrene on days 3, 5, and 7 after the i.p. inoculation of LoVo cells. In group 5, mice were injected i.p. with 200 L of serum-free medium containing 16 g/mL polybrene on days 3, 5, and 7. Next, the animals were injected i.p. with 5-FC (700 mg/kg body weight/day), 5-FU (500 mg/kg body weight/day), or PBS from day 10 to day 16. The animals of each group were observed for body weight loss, preterminal manifestations, and survival until day 42. The animals were killed before the end of the observation period when they developed excessively large tumors or when there were other signs of animal distress.
Evaluation of BM suppression
BALB/c-nu/nu mice were inoculated with parental LoVo cells, divided randomly into the five groups, and injected with retrovirus-producing cells or serum-free medium as described above. The animals were then injected with 5-FC, 5-FU, or PBS as described above from day 10 to day 13 and killed on day 14. Each group consisted of three animals. Genomic DNA and total RNA were extracted from various tissues and analyzed as described below. The femur was dissected out from each mouse, and the BM cells were flushed into ice-cold RPMI 1640 medium using a 21-gauge needle. Single-cell suspensions were obtained by repeated gentle aspiration through the needle. The BM cells were analyzed for colony formation ability in a semisolid culture medium as described previously. 26 The remaining BM cells were smeared quickly on a glass slide, dried with a fan, and fixed with methanol for 5-10 minutes. The slides were then stained with a mixture of Giemsa and Wright staining solutions containing methylene blue, eosin, azure, methanol, and glycerol for 30 minutes. The karyocytes, BM cells with nuclei, and mature erythrocytes were counted under a microscope, and the ratios of karyocytes to mature erythrocytes (K:E) were calculated. The K:E ratios were determined five times for each mouse.
Analysis of CD transduction and expression
Genomic DNA and total RNA were extracted from the liver, BM, brain, gastrointestinal mucosa, and i.p. disseminated CRCs according to the standard protocol. 27 The oligonucleotide primers used for amplification of the CD gene were designed according to the published data 28 and were 5Ј-TGTCGTATCCCAACGGTGAAGC-3Ј (forward) and 5Ј-CTCCAGCATCTCTTTAACGCG-3Ј (reverse), resulting in amplification of a 431-bp CD gene fragment. Genomic DNA samples were amplified with the primers of the CD gene for 40 cycles at an annealing temperature of 55°C using a thermal cycler (Perkin-Elmer, Norwalk, Conn). CD expression in various tissues was examined by RT-PCR. Purified total RNA (2.5 g) was used for cDNA synthesis using murine leukemia virus reverse transcriptase (Promega, Madison, Wis) with oligo(dT) 16 primers. A total of 20 l of reverse transcription products from each sample was amplified with the primers of the CD gene for 45 cycles with Taq polymerase (Stratagene, La Jolla, Calif) in PCR at an annealing temperature of 55°C. CD expression in various tissues was also examined by Northern blot analysis. Purified total RNA (20 g) was electrophoresed through a 1% agarose gel containing 6% formaldehyde, transferred to a Hybond-N ϩ membrane (Amersham, Arlington Heights, Ill), and hybridized with the 32 P-labeled CD gene according to the standard protocol. 27 
Statistics
The results are expressed as means Ϯ SD and were analyzed for statistical significance using the Student t test. A P value of Ͻ.05 was considered to indicate a significant difference between groups.
RESULTS
In vitro sensitivity to 5-FC of retrovirus-infected tumor cells
To investigate whether the 204-bp CEA promoter core region can induce CEA-producing cell-selective gene expression, various types of tumor cells were infected with LNCX, pCD2, CEA204/CD, or G1NaCEA204/CD retroviruses, and the bulk of G418-resistant cells were expanded and used as retrovirus-infected cells. There were no significant differences in the generation time and morphological appearance between the retrovirusinfected cells and the corresponding parental cells (data not shown). Previous studies have shown a correlation between the secretion levels of CEA protein and CEA transcription. 29 -31 The CEA protein concentrations of media were quantified by immunoassay to evaluate the transcriptional levels of the CEA gene in the tumor cells used in the experiments. As shown in Table 1 , human CRC WiDr, SW1463, and LoVo cells produced considerable amounts of CEA protein. Conversely, human renal cell carcinoma RC9406 cells, human gastric carcinoma MKN1 cells, and human hepatocellular carcinoma Hep3B cells did not produce detectable levels of CEA protein. The sensitivity of tumor cell lines to 5-FU was assessed before estimating the sensitivity to 5-FC. All parental cell lines were sensitive to 5-FU at low micromolar concentrations, with IC 50 values mentioned before of 0.9 -3.5 M (Table 1) , and there were no significant differences in the sensitivity to 5-FU between the parental and retrovirus-infected cell lines (data not shown). The sensitivity of the retrovirus-infected and parental cells to 5-FC was then examined. There were no significant differences in the sensitivity to 5-FC between the LNCX retrovirus-infected cells and the corresponding parental cells (data not shown). Conversely, all of the pCD2 retrovirus-infected cell lines were found to be much more sensitive to 5-FC than the corresponding LNCX retrovirus-infected lines, and IC 50 values to 5-FC were ϳ1/20 to 1/30 ( Table 1) . The CEA204/CD retrovirus-infected CRC WiDr, SW1463, and LoVo cells were also much more susceptible to 5-FC than the corresponding LNCX retrovirus-infected cells, and exhibited 10-to 23-fold higher sensitivity to 5-FC. The CEA204/CD retrovirus-infected non-CRC RC9406, Hep3B, and MKN1 cells exhibited slightly higher sensitivity to 5-FC than the corresponding LNCX retrovirusinfected cells, and there was a small shift in the IC 50 to 5-FC, presumably because of the influence of the virus enhancer existing in the LTR region of the retrovirus vector on the CEA promoter core region. Because the G1NaCEA204/CD retrovirus vector contains an expression cassette consisting of the CEA promoter core region and the CD gene in the U3 region of the 3Ј LTR, a higher and more selective expression of the CD gene was achieved compared with the CEA204/CD retrovirus vector. Although IC 50 values to 5-FC of the G1NaCEA204/CD retrovirus-infected CRC cells were ϳ1/18 to 1/30 of those of the corresponding LNCX retrovirus-infected cells, the 5-FC IC 50 values of the G1NaCEA204/CD retrovirus-infected non-CRC cells were very similar to those of the corresponding LNCX retrovirus-infected cells, indicating that the insertion of the expression cassette mentioned previously into the U3 region of the 3Ј LTR of a retrovirus construct can induce CRC-selective CD gene expression more efficiently and more stringently.
In vivo bystander effect of CD gene-modified CRC xenografts
To investigate the in vivo bystander effect caused by CD-transduced CRC, CRC xenograft experiments were performed. The nude mice inoculated with parental LoVo cells developed rapidly growing tumors despite 5-FC treatment, and the first animal died on day 50 after the implantation of the CRC xenograft (Fig 2) . Conversely, the tumors of mice inoculated with CEA204/CD retrovirus-infected LoVo cells and treated with 5-FC grew slowly until day 40, and did not grow significantly or even reduce thereafter during a 50-day observation period. The tumors of mice inoculated with a mixture of CEA204/CD retrovirus-infected and parental LoVo cells followed by 5-FC treatment also grew slowly compared with those inoculated with parental LoVo cells, and the growth pattern of these tumors was similar to that of CEA204/CD retrovirus-infected xenografts. Although the tumor volume at the time of initiation of 5-FC treatment was significantly larger in animals inoculated with a cell mixture than in those inoculated with parental LoVo cells, the tumor volume was significantly smaller on days 45 and 50. All animals were killed on day 50, and the s.c. tumors were resected for routine histological examination. Consistent with the previous report, 32 significant necrotic and fibrotic areas with a marked infiltration of fibrocytes and lymphocytes were observed in tumors consisting of CEA204/CD retrovirus-infected cells or a mixture of parental and CEA204/CD retrovirus-infected cells, whereas there were few infiltrating cells in tumors consisting of parental LoVo cells (data not shown).
In vivo CD gene transfer into mice with i.p. disseminated CRCs Athymic nude mice with i.p. disseminated CRCs were injected i.p. with LNCX, pCD2, or CEA204/CD retrovirus-producing cells followed by 5-FC, 5-FU, or PBS treatment. Genomic DNA was extracted from various tissues, and a CD gene fragment was amplified by PCR. An amplified 431-bp CD fragment was obtained from DNA samples extracted from the i.p. disseminated CRCs, BM, and gastrointestinal mucosa of mice injected i.p. with CEA204/CD or pCD2 retrovirus-producing cells (Fig 3A) . The CD transcript was detected by RT-PCR in the i.p. disseminated CRCs and BM but not in the gastrointestinal mucosa of mice injected with pCD2 retrovirus-producing cells. In contrast, the CD transcript was detected solely in the i.p. disseminated CRCs but not in the BM or gastrointestinal mucosa of mice injected with CEA204/CD retrovirus-producing cells (Fig 3B) . The results were subsequently confirmed by Northern blot analysis. Although 5.1 kb of retrovirus genomic RNA was dimly observed in RNA samples extracted from the i.p. disseminated CRCs and BM of mice injected with CEA204/CD retrovirus-producing cells, a distinct 1.2-kb CD transcript was observed solely in RNA samples extracted from CRCs (Fig 4) .
To examine the therapeutic effects of in vivo gene therapy with the CD gene directed by the CEA promoter core region, five different treatment protocols were performed as described in Materials and Methods. All animals treated with 5-FU began to suffer from diarrhea approximately from day 15, resulting in severe body weight loss and hunched posture. All animals in this group died or were killed due to evident signs of distress on day 18. All animals injected with LNCX retrovirusproducing cells followed by 5-FC treatment and those injected with CEA204/CD retrovirus-producing cells followed by PBS treatment had heavy tumor burdens and diarrhea; these animals died or were killed on day 22 and day 25, respectively. Although observation was terminated due to heavy tumor burdens on day 42, two of seven animals injected with pCD2 retrovirus-producing cells followed by 5-FC treatment were alive. Furthermore, five of seven animals injected with CEA204/CD retrovirus-producing cells followed by 5-FC treatment were alive with better activity on day 42.
In vivo gene therapy-related BM suppression
To examine the in vivo gene therapy-related toxicity on the BM, K:E ratios and CFU values were estimated. Our preliminary experiments showed that the K:E ratios in the extracts from the femoral BM of BALB/c-nu/nu mice generally ranged from 60% to 70%; CFU values from 1 ϫ 10 5 femoral BM cells were usually between 90 and 110. As shown in Table 2 , severe BM suppression was observed in mice treated with 5-FU, whereas BM suppression was not observed in mice injected with LNCX retrovirus-producing cells followed by 5-FC treatment or in mice injected with CEA204/CD retrovirus-producing cells followed by PBS treatment. The K:E ratio and CFU value in the same animal were shown to be correlated with each other. Although significantly decreased K:E ratios and CFU values were observed in mice injected with pCD2 retrovirus-producing cells followed by 5-FC treatment, a significant decrease in K:E ratios or CFU values was not observed in mice injected with CEA204/CD retrovirus-producing cells followed by 5-FC treatment.
DISCUSSION
CEA is one of the most useful tumor markers and tumor-monitoring markers for conventional anticancer therapy, because some tumors of epithelial cell origin produce much higher levels of CEA than the normal colon. Although the precise control mechanism of CEA expression is still unclear, it has been shown that cisacting sequences which convey cell type-selective expression of the CEA gene may be contained within ϳ400 bp upstream from the translational start site of the CEA gene. 7 Richards et al 12 have demonstrated that the CEA promoter may be located between Ϫ90 and ϩ69 bp upstream from the transcriptional start site and that the essential sequences of the CEA promoter may reside between Ϫ90 and Ϫ17 bp of the transcriptional start site of the CEA gene. Chen et al 33 have demonstrated that the CEA promoter region between Ϫ123 and Ϫ28 bp upstream from the transcriptional start site contains binding regions for several important trans-acting factors such as Sp-1 and upstream stimulatory factor. We have isolated the 204-bp CEA promoter regions, which are located between Ϫ135 and ϩ69 bp upstream from the transcriptional start site, from a high CEA-producing human CRC and from its adjacent normal colon mucosa, and have demonstrated that the sequences of both CEA promoter regions are identical and do not contain the classic TATA or CAAT boxes at their expected positions. 13 In the present study, it was shown that the 204-bp CEA promoter core region could direct CEA-producing cell-selective CD expression, resulting in a 10-to 30-fold higher susceptibility to 5-FC compared with those infected with control LNCX retroviruses. The WiDr cells, which have the lowest ability to produce CEA among the CRC cell lines used in our experiments, showed the highest IC 50 value to 5-FC when infected with CEA204/CD or G1NaCEA204/CD retroviruses. The sensitivity to 5-FC of CEA-nonproducing non-CRC cells was not affected by CEA204/CD or G1NaCEA204/CD retrovirus infection. It was also shown that when the expression cassette was inserted into the U3 region of the retrovirus 3Ј LTR, more efficient and more stringent CD expression was achieved in the CEA-producing CRC cells, probably due to duplication of the expression cassette after reverse transcription of the recombinant retrovirus genomic RNA in the infected cells and due to escape of the retrovirus enhancer existing in the U3 region of the retrovirus LTR from the interference. Thus, it was suggested that insertion of an expression cassette consisting of a tissue-selective promoter into the U3 region of the retrovirus 3Ј LTR may result in more efficient and more stringent expression of an exogenous gene. Furthermore, our results suggest that the retrovirus-mediated transduction of the CD gene under the control of the CEA promoter core region followed by 5-FC treatment may solely eliminate the high CEAproducing tumors in vivo without affecting the low CEA-producing normal colon and CEA-nonproducing tissues.
Consistent with the results of previous reports, 4,12,32,34 -36 the established s.c. CD-transduced CRCs were susceptible to systemic 5-FC treatment. It must be stressed that the bulk of G418-resistant CRC cells were used as CD-transduced cells in the present study, although the best CD-transduced clone was used in most previous studies. Therefore, the present results may be more realistic when gene therapy using the CD gene is employed in clinical practice. Furthermore, it was shown that the growth of tumors consisting of the bulk of CEA204/CD retrovirus-infected and parental CRC cells was significantly suppressed by systemic 5-FC treatment, and the growth pattern was similar to that of CD-transduced CRCs treated with 5-FC, indicating that a profound bystander effect was induced in vivo by the CD gene and 5-FC system. Existence of the bystander effect is critical for achieving effective gene therapy against cancer, because it appears impossible to transfer a therapeutic gene into all target tumor cells in vivo by the techniques that are currently available.
Retrovirus-mediated gene transfer is the method employed in the majority of approved gene therapy clinical protocols. No serious side effects have been reported thus far in clinical gene therapy trials using retrovirus systems. Importantly, there is no evidence suggesting the contamination of wild-type replication-competent retroviruses or the potential for insertional mutagenesis. 37 Although the efficiency of gene transduction by retroviruses is relatively low, retroviruses, unlike adenoviruses, do not induce significant immune responses in the host. 38 Therefore, it appears possible to repeat in vivo gene transfer, which would lead to increased gene transduction efficiency. To improve the efficiency of the retrovirus-mediated gene transfer, several attempts, such as concentration of the retroviruses and modification of the retrovirus-packaging cells, were reported. 18, 39, 40 In the present study, we established retrovirusproducing clones by the transinfection protocol. The reason for selecting this method rather than direct isolation of vector-transfected producing clones is that the resultant clones generally produce much higher titers of retroviruses and contain only one vector integrant, allowing their structure to be confirmed unambiguously. 41 Furthermore, to increase the gene transduction efficiency, we injected retrovirus-producing cells but not retroviruses into the murine peritoneal cavity. The usefulness of this approach was originally validated in rat glioma models. 42, 43 In vivo gene therapy is apparently more applicable in clinical trials for the treatment of various types of cancer than ex vivo gene therapy. To perform in vivo gene therapy against cancer using suicide genes, it is requisite to achieve tumor cell-selective suicide gene expression. Retrovirus vectors are attractive for transferring suicide genes into a tumor, because they integrate only into actively dividing cells, such as tumor cells, whereas most normal cells surrounding a tumor are in a quiescent, nonreceptive stage of cell growth. However, there are noncancerous normal dividing cells in vivo, such as BM cells and gastrointestinal epithelial cells. It was shown here that an i.p. injection of pCD2 retrovirus-producing cells caused CD expression in i.p. disseminated CRC xenografts and femoral BM cells, resulting in severe BM suppression. Conversely, when the CEA204/CD retrovirus-producing cells were injected, CD transduction was observed in both CRC xenografts and BM cells but CD expression was restricted to CRC xenografts. In both cases, the CD gene fragment was amplified by PCR from DNA samples extracted from the stomach and small intestine, but the CD gene fragment was not amplified by RT-PCR from the RNA samples. Therefore, it is suggested that the retroviruses produced in the peritoneal cavity did not infect but merely stuck to the gastrointestinal epithelial cells.
The present study showed that retroviruses produced in situ could efficiently transduce i.p. disseminated CRCs, although the transduction efficiency was not estimated. The study also showed that systemic 5-FC administration caused severe BM suppression solely in animals injected i.p. with the pCD2 retrovirus-producing cells but not in those injected with the CEA204/CD retrovirus-producing cells. A plausible explanation is that in animals injected with pCD2 retrovirus-producing cells, the CD gene was expressed both in a fraction of CRC xenografts and in pCD2 retrovirus-producing cells; in addition, higher levels of 5-FU were produced in the peritoneal cavity compared with those animals injected with the CEA204/CD retrovirus-producing cells, resulting in higher serum concentrations of 5-FU. However, this possibility may be unlikely, because the serum 5-FU levels were below the threshold not only in animals injected with the CEA204/CD retrovirus-producing cells but also in those animals injected with the pCD2 retrovirus-producing cells (data not shown). Therefore, we speculate that the pCD2 retroviruses produced in the peritoneal cavity entered into blood, were transferred to the BM, and infected the BM cells that were dividing rapidly, resulting in CD expression in the BM cells. Conversely, CD expression did not occur in the CEA204/CD retrovirus-infected BM cells due to restriction by the CEA promoter core region. Therefore, it is suggested that the death of animals injected with the pCD2 retrovirus-producing cells followed by 5-FC treatment was due to tumor burdens and BM suppression, whereas the death of animals injected with the CEA204/CD retrovirus-producing cells followed by 5-FC treatment was solely due to heavy tumor burdens. Although more precise investigations need to be performed, our present results may warrant the safety of in vivo gene therapy against CRC using the CD gene under the transcriptional control of the CEA promoter core region.
